December 29, 2011 — Navitoclax, a novel BH3 mimetic that blocks the function of BCL-2, has shown significant antileukemic activity in patients with chronic lymphocytic leukemia (CLL) in a phase 1 ...
14don MSN
AbbVie wins FDA nod for Venclexta-acalabrutinib combo in first-line chronic lymphocytic leukemia
AbbVie (ABBV) said Friday that the U.S. FDA has approved a supplemental new drug application for its combination regimen of Venclexta (venetoclax) and acalabrutinib to treat previously untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results